One of the more volatile healthcare stocks of recent days, Liquidia Technologies (NASDAQ: LQDA), had quite the up session on Friday. Investors lifted the share price of the drug developer by almost 21%, following a series of relatively small but confidence-boosting insider buys.  

Liquidia has been an up-and-down stock due to developments on the legal front, specifically a patent infringement dispute it was engaged in against plaintiff United Therapeutics (NASDAQ: UTHR). On Monday, a district court in Delaware ruled in favor of United, finding that Liquidia had infringed one of the two patents in dispute with its Yutrepia, the generic version of an inhalation powder that treats pulmonary arterial hypertension (PAH). 

Both United and Liquidia claimed victory in the dispute, as the latter was not found to infringe both patents.

Continue reading

Source Fool.com